Regulatory approval

Published by the European Medicines Agency. Approved

Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX or FOLFIRI.

This is written in the approval document.

Citation

Amgen Europe B.V. Vectibix (panitumumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf. Revised July 2022. Accessed March 28, 2024.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (1) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Oxaliplatin, Panitumumab
EMA (1) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Irinotecan, Panitumumab

Contributions

Date Contributor Description
2024-10-20 Van Allen lab Adding EMA approvals for use to database
2015-03-31 European Medicines Agency Indication received approval from the European Commission.